Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Mar;59(3):434–441. doi: 10.2967/jnumed.117.202945

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by the Society of Nuclear Medicine and Molecular Imaging.

PMC Copyright notice

FIGURE 4. — ⁶⁸Ga-PSMA-11 PET/CT in 75-y-old man with BCR (PSA level, 2.88 ng/mL; doubling time, 4.5 mo) of initially high-risk prostate cancer (Gleason score, 8; pT3) 4 y after primary radiotherapy without androgen deprivation therapy. Q1 listed androgen deprivation therapy as planned treatment. ⁶⁸Ga-PSMA-11 PET/CT showed focal ⁶⁸Ga-PSMA-11 uptake (SUV_max, 3.9) in right prostate lobe (yellow arrows). Intended treatment after ⁶⁸Ga-PSMA-11 PET/CT (Q2) was surgery, which patient refused because of potential side effects. Actual management was thus androgen deprivation therapy as indicated on Q1 (no management change). (A) Coronal ⁶⁸Ga-PSMA-11 PET/CT. (B) Coronal CT. (C) Sagittal ⁶⁸Ga-PSMA-11 PET/CT. (D) Sagittal CT. (E) Axial ⁶⁸Ga-PSMA-11 PET/CT. (F) ⁶⁸Ga-PSMA-11 PET maximum-intensity projection. Yellow arrows denote focal tracer uptake consistent with intraprostatic recurrence.